Mental health disorders such as depression and anxiety often lack effective treatments, driving the need for innovative therapeutic interventions. Traditional pharmaceutical approaches may not provide sufficient relief for all patients, and there is growing interest in alternative and complementary therapies. The development of novel treatments requires rigorous research, standardized manufacturing, and regulatory approval.

Cubed Biotech is a biotechnology company focused on the cultivation, extraction, and synthesis of natural entheogens, including psilocybin, mescaline, and DMT, for the development of psychedelic medicines. The company aims to address unmet needs in mental healthcare by producing Active Pharmaceutical Ingredients (APIs) and investigational medicinal products. Cubed Biotech employs cGMP mycological cultivation methods and extraction techniques to produce psilocybin and psilocin from unique psilocybe strains. The company is also developing a hybrid non-hallucinogenic psychedelic molecule that selectively binds to the 5-HT1A receptor, as well as a stacked multiple-API formula "Ayahuasca pill" for clinical trials.

cGMP-compliant cultivation of psilocybe mushrooms for psilocybin and psilocin production

Extraction and purification processes using (M)ethanol and water to create Active Pharmaceutical Ingredients (APIs)

Development of a non-hallucinogenic psychedelic molecule targeting the 5-HT1A receptor

Research and development of a stacked multiple-API formula "Ayahuasca pill"

Production of mescaline from peyote, San Pedro, and Peruvian Torch cacti

Extraction of DMT from plants and vines for Ayahuasca formulations

The primary target audience includes pharmaceutical companies, clinical researchers, and healthcare providers focused on developing and providing innovative treatments for mental health disorders.